Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Journal of the Neurological Sciences|May 22, 2016
Impact of a switch to fingolimod on depressive symptoms in patients with relapsing multiple sclerosis: An analysis from the EPOC (Evaluate Patient OutComes) trialSamuel F Hunter, Mark Agius, Deborah M Miller, et al.
Multiple Sclerosis and Related Disorders|October 11, 2024
Safety, tolerability, and efficacy of diroximel fumarate in a cohort of Black patients with multiple sclerosis from the phase 3 EVOLVE-MS-1 studySamuel F Hunter, John W Lindsey, Benjamin Osborne, et al.
Multiple Sclerosis and Related Disorders|July 28, 2020
Switching to fingolimod in PREFERMS: Effect of treatment history and naïvety on clinical, MRI and treatment satisfaction outcomes<sup>✰</sup>Samuel F Hunter, Florian P Thomas, Mark Cascione, et al.
Multiple Sclerosis and Related Disorders|August 13, 2015
Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosisEdward Fox, Keith Edwards, Gordon Burch, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 26, 2018
Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trialJeffrey A Cohen, Samuel F Hunter, Theodore R Brown, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|November 21, 2022
Satisfaction with alemtuzumab in relapsing multiple sclerosis patients: Results from the real-world PRO-ACT studySibyl Wray, Francois Jacques, Tamara A Miller, et al.
Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging|May 12, 2018
Fingolimod's Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MS-MRIUSRobert Zivadinov, Jennie Medin, Nasreen Khan, et al.
Archives of Neurology|September 15, 2010
Paraneoplastic jaw dystonia and laryngospasm with antineuronal nuclear autoantibody type 2 (anti-Ri)Sean J Pittock, Joseph E Parisi, Andrew McKeon, et al.
Advances in Therapy|February 25, 2022
Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 StudySibyl Wray, Florian Then Bergh, Annette Wundes, et al.
Neurology and Therapy|June 24, 2021
Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS StudiesSamuel F Hunter, Rany A Aburashed, Raed Alroughani, et al.
Pageof 3